Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06898983
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia
Sponsor: Anhui Provincial Hospital
Interventions
Romiplostim N01
Updated 1 time since 2025 Last updated: Mar 27, 2025 Started: Mar 31, 2025 Primary completion: Jun 30, 2026 Completion: Feb 28, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Cancer Treatment-induced Thrombocytopenia (CTIT) and is currently actively recruiting participants. Anhui Provincial Hospital leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Anhui Provincial Hospital
Data source: Anhui Provincial Hospital
For direct contact, visit the study record on ClinicalTrials.gov .